IL-17 binding proteins
First Claim
Patent Images
1. A method for treating a subject for a disease or a disorder by administering to the subject a binding protein such that treatment is achieved, wherein the binding protein comprises first and second polypeptide chains, wherein the first polypeptide chain comprises a first VD1-(X1)n-VD2-C—
- (X2)n, whereinVD1 is a first heavy chain variable domain;
VD2 is a second heavy chain variable domain;
C is a heavy chain constant domain;
X1 is a linker with the proviso that it is not CH1; and
X2 is an Fc region;
n is 0 or 1; and
wherein the second polypeptide chain comprises a second VD1-(X1)n-VD2-C—
(X2)n, whereinVD1 is a first light chain variable domain;
VD2 is a second light chain variable domain;
C is a light chain constant domain;
X1 is a linker with the proviso that it is not CH1;
X2 does not comprise an Fc region; and
n is 0 or 1;
wherein the binding protein is capable of binding human IL-17 and TNF-α
;
wherein, in the first polypeptide chain, said VD1 or VD2 heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;
565, 670, 720, 740, 845, and 875; and
wherein, in the second polypeptide chain, said VD1 or VD2 light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;
570, 675, 725, 745, 850, and 880;
and wherein said disease or disorder is selected from the group consisting of arthritis, crohn'"'"'s disease, ulcerative colitis, psoriasis, uveitis, Bechet'"'"'s disease, and a spondyloarthropathy.
2 Assignments
0 Petitions
Accused Products
Abstract
Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
145 Citations
45 Claims
-
1. A method for treating a subject for a disease or a disorder by administering to the subject a binding protein such that treatment is achieved, wherein the binding protein comprises first and second polypeptide chains, wherein the first polypeptide chain comprises a first VD1-(X1)n-VD2-C—
- (X2)n, wherein
VD1 is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CH1; and X2 is an Fc region; n is 0 or 1; and wherein the second polypeptide chain comprises a second VD1-(X1)n-VD2-C—
(X2)n, whereinVD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 does not comprise an Fc region; and n is 0 or 1; wherein the binding protein is capable of binding human IL-17 and TNF-α
;wherein, in the first polypeptide chain, said VD1 or VD2 heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;
565, 670, 720, 740, 845, and 875; andwherein, in the second polypeptide chain, said VD1 or VD2 light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;
570, 675, 725, 745, 850, and 880;and wherein said disease or disorder is selected from the group consisting of arthritis, crohn'"'"'s disease, ulcerative colitis, psoriasis, uveitis, Bechet'"'"'s disease, and a spondyloarthropathy. - View Dependent Claims (2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 30, 31, 34, 35, 38, 39, 42, 43)
- (X2)n, wherein
-
3. A method for treating a subject for a disease or a disorder by administering to the subject a binding protein such that treatment is achieved, wherein the binding protein is capable of binding two antigens comprising four polypeptide chains, wherein two polypeptide chains comprise VD1-(X1)n-VD2-C—
- (X2)n, wherein
VD1 is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CH1; and X2 is an Fe region, n is 0 or 1; and wherein two polypeptide chains comprise VD1-(X1)n-VD2-C—
(X2)n, whereinVD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 does not comprise an Fe region; and n is 0 or 1; wherein the binding protein is capable of binding human IL-17 and TNF-alpha; wherein in the two first polypeptide chains, said VD1 or VD2 heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;
565, 670, 720, 740, 845, and 875; andwherein, in the two second polypeptide chains, said VD1 or VD2 light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ NOs;
570, 675, 725, 745, 850, and 880;and wherein said disease or disorder is selected from the group consisting of arthritis, crohn'"'"'s disease, ulcerative colitis, psoriasis, uveitis, Bechet'"'"'s disease, and a spondyloarthropathy. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 32, 33, 36, 37, 40, 41, 44, 45)
- (X2)n, wherein
-
24. A method for treating a subject for a disease or a disorder by administering to the subject a binding protein such that treatment is achieved, wherein the binding protein comprises a polypeptide chain comprising VD1-(X1)n-VD2-C—
- (X2)n, wherein
VD1 is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CH1; and X2 is an Fc region; n is 0 or 1; and wherein the binding protein is capable of binding human IL-17 and TNF-α
; andwherein, in the polypeptide chain, said VD1 or VD2 heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;
565, 670, 720, 740, 845; and
875;and wherein said disease or disorder is selected from the group consisting, of arthritis, crohn'"'"'s disease, ulcerative colitis, psoriasis, uveitis, Bechet'"'"'s disease, and a spondyloarthropathy. - View Dependent Claims (25, 26, 27)
- (X2)n, wherein
-
28. A method for treating a subject for a disease or a disorder by administering to the subject a binding protein such that treatment is achieved, wherein the binding protein comprises a polypeptide chain comprising VD1-(X1)n-VD2-C—
- (X2)n, wherein
VD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 does not comprise an Fc region; and n is 0 or 1; wherein the binding protein is capable of binding human IL-17 and TNF-a, and wherein, in the polypeptide chain, said VD1 or VD2 light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;
570, 675, 725, 745, 850, and 880;and wherein said disease or disorder is selected from the group consisting of arthritis, crohn'"'"'s disease, ulcerative colitis, psoriasis, uveitis, Bechet'"'"'s disease, and a spondyloarthropathy. - View Dependent Claims (29)
- (X2)n, wherein
Specification